Biogen highlighted new Phase 2 CELIA study data for diranersen at AAIC 2026, reporting meaningful clinical outcomes and strong biomarker responses in early Alzheimer’s patients. While no specific effect sizes were provided in the article, the update is a constructive read-through for efficacy signals at this stage and may support incremental upside sentiment for BIIB.
Biogen highlighted new Phase 2 CELIA study data for diranersen at AAIC 2026, reporting meaningful clinical outcomes and strong biomarker responses in early Alzheimer’s patients. While no specific effect sizes were provided in the article, the update is a constructive read-through for efficacy signals at this stage and may support incremental upside sentiment for BIIB.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
